Mode
Text Size
Log in / Sign up

Urinary Incontinence

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Urinary Incontinence

75 trials tracked for Urinary Incontinence: 22 in phase 3 or 4 and 6 with published results. The most-cited published study has 220 citations.

75Trials tracked
22Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 8 Phase 3 14 Phase 2 7 Phase 1 2 Other / NA 44
  1. Phase 3 Impact of Robot-assisted Radical Prostatectomy Technique on Short-term Continence Recovery Completed · 220 cited
  2. Phase 3 ATLAS: Ambulatory Treatments for Leakage Associated With Stress Completed · 148 cited
  3. Phase 3 Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder Completed · 99 cited
  4. Phase 3 Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS) Completed · 25 cited
  5. Phase 3 Chlorhexidine vs. Iodine for Vaginal Preparation in Urogynecologic Procedures Completed · 9 cited
  6. Phase 4 Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence Completed · 1 cited
Show 44 more trials
  1. Phase 4 Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease Completed
  2. Phase 4 Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics Completed
  3. Phase 4 Lessons on Urethral Lidocaine in Urodynamics Completed
  4. Phase 4 Outcomes of Anterior Colporrhaphy Versus Graft Reinforced Anterior Prolapse Repair Completed
  5. Phase 4 Value of Urodynamic Evaluation Completed
  6. Phase 4 A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy Completed
  7. Phase 4 TOMUS-Trial Of Mid-Urethral Slings Completed
  8. Phase 3 Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder Completed
  9. Phase 3 Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients Completed
  10. Phase 3 A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity Completed
  11. Phase 3 Platelet-Rich Plasma for Stress Urinary Incontinence Completed
  12. Phase 3 Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence Completed
  13. Phase 3 Comparison of Surgical Procedures to Reduce Urinary Stress Incontinence Completed
  14. Phase 3 An Implantable Microstimulator for the Chronic Treatment of Refractory Urinary Urge Incontinence Completed
  15. Phase 3 Bladder Scan of Residual Urine With New Catheter Completed
  16. Phase 3 A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence Completed
  17. Phase 2 DBPC Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine in Subjects With Urinary Incontinence Completed
  18. Phase 2 Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence Completed
  19. Phase 2 Mirabegron For Erectile Dysfunction Completed
  20. Phase 2 Autologous Cell Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery Completed
  21. Phase 2 BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence Completed
  22. Phase 2 Acupuncture for Urinary Incontinence Completed
  23. Phase 2 A Research Study for Patients With Overactive Bladder Completed
  24. Phase 1 Autologous Muscle Derived Cells for Underactive Bladder Completed
  25. Phase 1 Two Devices for Reflex Voiding Following Spinal Cord Injury Completed
  26. N/A An Exploratory Investigation of the Effects of Single Use vs. Reuse Catheters in Intermittent Catheterization Completed
  27. N/A Effect of Electroacupuncture Versus PFMT Plus Solifenacin for Mixed Urinary Incontinence Completed
  28. N/A Controlled Trial of Tele-Support and Education for Womens Health Care in CBOCs Completed
  29. N/A Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium Completed
  30. N/A Postpartum Pelvic Floor Muscle Training in Women With and Without Injured Pelvic Floor Muscles Completed
  31. N/A Fistula Reintegration Pilot Completed
  32. N/A Improving Care for Women With Urinary Incontinence (EMPOWER) Completed
  33. N/A Enhancing Conservative Treatment for Urge Incontinence Completed
  34. N/A Feasibility of Parasacral Transcutaneous Electrical Nerve Stimulation PTENS for Voiding Dysfunction in Peds Population Completed
  35. N/A Mobile App-treatment of Mixed and Urgency Urinary Incontinence in Women Completed
  36. N/A A Pilot Clinical Trial of TENA Identifi in the Nursing Home Setting Completed
  37. N/A Conservative Treatment of Postprostatectomy Incontinence Completed
  38. N/A Perioperative Post-Prostatectomy Incontinence Home Telehealth Program Completed
  39. N/A Dose-response of Physical Exercise on Pelvic Floor Muscle Function in Postmenopausal Women With Urinary Incontinence Completed
  40. N/A Laser Therapy for Treatment of Urogenital Symptoms in Women Completed
  41. N/A The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence Completed
  42. N/A Investigation of the Ability of the TENA SmartCare Change Indicator to Reduce the Number of Manual Checks Between Changes of Absorbing Incontinence Products Completed
  43. N/A A Multi-Center Trial of Botox for Severe Urge Urinary Incontinence Completed
  44. N/A Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II) Completed

Showing the 50 most-cited and recently-updated of 75 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Urinary Incontinence: what the trials found

Pharmacological and procedural interventions for urinary incontinence show varying degrees of efficacy. OnabotulinumtoxinA treatment is associated with significant reductions in the daily average number of urinary incontinence episodes 2 and a reduction in micturition episodes 2. Cystoscopic injection of Botox into the bladder also demonstrated a statistically significant reduction in daily incontinence episodes 5. Furthermore, multiple trials involving OnabotulinumtoxinA reported high percentages of patients achieving substantial reductions (≥50%, ≥75%, or ≥90%) in daytime urinary incontinence episodes across multiple treatment cycles 16, and some studies noted a 100% reduction in episodes for a portion of the cohort 19.

Surgical interventions show measurable outcomes in success rates. Retropubic mid-urethral sling (TVT) resulted in objective treatment success rates of approximately 77-81% at 12 months 8. The Burch Modified Tanagho procedure showed a statistically significant difference in 24-month cumulative stress-specific success rates between study arms 22. Grafted anterior prolapse repair was associated with lower rates of recurrent Stage II or greater anterior vaginal prolapse compared to other methods 9.

Behavioral and supportive interventions provide evidence for symptom management. Behavioral therapy resulted in a significant number of patients reporting 'Much Better' or 'Very Much Better' on the Patient Global Impression of Improvement (PGI-I) at both 3 and 12 months, with a corresponding reduction in bothersome stress incontinence symptoms 11. Office evaluation protocols were associated with high rates of patients meeting or exceeding a 70% decrease in UDI scores and improved patient global impressions 7.

Recent results — preliminary, needs further review

  • Patient education was associated with significant improvements in UI symptoms as measured by the ICIQ-UI SF (p<0.001) 1.
  • A study on the interaction of anticholinergic treatment and the inflammatory milieu showed no statistically significant difference in inflammatory markers across various drugs including Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine (p=0.6497) 4.

For the clinician treating this condition

  • OnabotulinumtoxinA is associated with significant reductions in daily incontinence episodes and micturition frequency [2, 5].
  • Surgical interventions such as retropubic mid-urethral slings and Burch Modified Tanagho procedures demonstrate high success rates for managing symptoms [8, 22].
  • Behavioral therapy is an effective non-invasive option, with many patients reporting significant improvement in bothersome symptoms at 3 and 12 months 11.

AI synthesis of 11 cited trials, updated Jun 22, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.